Actualización en el Manejo de los Tumores Gástricos Neuroendocrinos: Una Revisión Narrativa
Palabras clave:
tumores neuroendocrinos, neoplasias gástricas, gastrinas, gastrinoma, síndrome de zollinger-ellison
Resumen
Introducción: Los tumores neuroendocrinos gástricos (G-NETs) son neoplasias raras, pero con un aumento en su incidencia. Se clasifican en tres tipos: I, II y III, que varían en comportamiento clínico y terapéutico. Objetivo: Este artículo revisa los avances en el diagnóstico y manejo de los G-NETs, con un enfoque en las estrategias terapéuticas actuales y emergentes. Metodología: Se realizó una revisión narrativa, integrando estudios recientes sobre diagnóstico, estadificación y tratamiento de los G-NETs. La búsqueda bibliográfica se efectuó en bases de datos como MEDLINE, EMBASE, Cochrane, entre otras, utilizando términos MeSH relevantes. Resultados: El manejo de los G-NETs varía según el subtipo. Los tumores tipo I se manejan principalmente con resección endoscópica y vigilancia. Los tumores tipo II requieren tratamiento del gastrinoma subyacente, mientras que los tipo III, más agresivos, demandan resección quirúrgica radical. En la enfermedad metastásica, las terapias con análogos de somatostatina y la terapia con radionúclidos son opciones viables. Conclusiones: Aunque los avances en el tratamiento de los G-NETs han mejorado los resultados, siguen existiendo desafíos, especialmente en casos avanzados y metastásicos. Se requiere investigación adicional para optimizar las estrategias terapéuticas.
Descargas
La descarga de datos todavía no está disponible.
Citas
Abbott, A., Sakellis, C. G., Andersen, E., Kuzuhara, Y., Gilbert, L., Boyle, K., Kulke, M. H., Chan, J. A., Jacene, H. A., & Van den Abbeele, A. D. (2018). Guidance on (177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division. Journal of Nuclear Medicine Technology, 46(3), 237–244. https://doi.org/10.2967/jnmt.118.209148
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017). The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. In CA: a cancer journal for clinicians (Vol. 67, Issue 2, pp. 93–99). https://doi.org/10.3322/caac.21388
Ammann, M., Kinney, M. A. O., Gudmundsdottir, H., Santol, J., Thiels, C. A., Warner, S. G., Truty, M. J., Kendrick, M. L., Smoot, R. L., Anderson, A. L., Halfdanarson, T. R., Nagorney, D. M., & Starlinger, P. P. (2024). Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis. In Annals of surgical oncology (Vol. 31, Issue 6, pp. 3976–3977). https://doi.org/10.1245/s10434-024-15264-2
Campana, D., Ravizza, D., Ferolla, P., Faggiano, A., Grimaldi, F., Albertelli, M., Ricci, C., Santini, D., Brighi, N., Fazio, N., Colao, A., Ferone, D., & Tomassetti, P. (2017). Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. Endocrine, 56(3), 633–638. https://doi.org/10.1007/s12020-016-1099-y
Caplin, M. E., Pavel, M., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L., Rindi, G., Langley, A., Martinez, S., Blumberg, J., & Ruszniewski, P. (2014). Lanreotide in metastatic enteropancreatic neuroendocrine tumors. The New England Journal of Medicine, 371(3), 224–233. https://doi.org/10.1056/NEJMoa1316158
Castillo, J. G., Filsoufi, F., Adams, D. H., Raikhelkar, J., Zaku, B., & Fischer, G. W. (2008). Management of patients undergoing multivalvular surgery for carcinoid heart disease: the role of the anaesthetist. British Journal of Anaesthesia, 101(5), 618–626. https://doi.org/10.1093/bja/aen237
Choi, C. K. (2014). Anesthetic considerations and management of a patient with unsuspected carcinoid crisis during hepatic tumor resection. Middle East Journal of Anaesthesiology, 22(5), 515–518.
Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., & Xu, Y. (2017). Trends in the Incidence , Prevalence , and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncology, 3(10), 1–2. https://doi.org/10.1001/jamaoncol.2017.0589
Dasari, A., Wallace, K., Halperin, D. M., Maxwell, J., Kunz, P., Singh, S., Chasen, B., & Yao, J. C. (2025). Epidemiology of Neuroendocrine Neoplasms in the US. JAMA Network Open, 8(6), e2515798. https://doi.org/10.1001/jamanetworkopen.2025.15798
Dell’Unto, E., Esposito, G., Rinzivillo, M., Marasco, M., Annibale, B., & Panzuto, F. (2024). Type 3 gastric neuroendocrine neoplasms: the rising promise of conservative endoscopic management. Frontiers in Medicine, 11, 1327864. https://doi.org/10.3389/fmed.2024.1327864
Delle Fave, G., O’Toole, D., Sundin, A., Taal, B., Ferolla, P., Ramage, J. K., Ferone, D., Ito, T., Weber, W., Zheng-Pei, Z., De Herder, W. W., Pascher, A., & Ruszniewski, P. (2016). ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology, 103(2), 119–124. https://doi.org/10.1159/000443168
Eads, J. R., Halfdanarson, T. R., Asmis, T., Bellizzi, A. M., Bergsland, E. K., Dasari, A., El-Haddad, G., Frumovitz, M., Meyer, J., Mittra, E., Myrehaug, S., Nakakura, E., Raj, N., Soares, H. P., Untch, B., Vijayvergia, N., & Chan, J. A. (2023). Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Endocrine-Related Cancer, 30(8). https://doi.org/10.1530/ERC-22-0206
Engevik, A. C., Kaji, I., & Goldenring, J. R. (2020). The Physiology of the Gastric Parietal Cell. Physiological Reviews, 100(2), 573–602. https://doi.org/10.1152/physrev.00016.2019
Exarchou, K., Kamieniarz, L., Tsoli, M., Victor, A., Oleinikov, K., Khan, M. S., Srirajaskanthan, R., Mandair, D., Grozinsky-Glasberg, S., Kaltsas, G., Howes, N., Pritchard, D. M., & Toumpanakis, C. (2021). Is local excision sufficient in selected grade 1 or 2 type III gastric neuroendocrine neoplasms? Endocrine, 74(2), 421–429. https://doi.org/10.1007/s12020-021-02775-1
Exarchou, K., Stephens, N. A., Moore, A. R., Howes, N. R., & Pritchard, D. M. (2022). New Developments in Gastric Neuroendocrine Neoplasms. Current Oncology Reports, 24(1), 77–88. https://doi.org/10.1007/s11912-021-01175-y
Fang, C., Wang, W., Feng, X., Sun, J., Zhang, Y., Zeng, Y., Wang, J., Chen, H., Cai, M., Lin, J., Chen, M., Chen, Y., Li, Y., Li, S., Chen, J., & Zhou, Z. (2017). Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. British Journal of Cancer, 117(10), 1544–1550. https://doi.org/10.1038/bjc.2017.315
Felder, S., Jann, H., Arsenic, R., Denecke, T., Prasad, V., Knappe-Drzikova, B., Maasberg, S., Wiedenmann, B., Pavel, M., Pascher, A., & Pape, U. F. (2019). Gastric neuroendocrine neoplasias: manifestations and comparative outcomes. Endocrine-Related Cancer, 26(9), 751–763. https://doi.org/10.1530/ERC-18-0582
Guo, X., Zhao, X., Huang, G., & Yu, Y. (2024). Advances in Endoscopic Diagnosis and Treatment of Gastric Neuroendocrine Neoplasms. Digestive Diseases and Sciences, 69(1), 27–35. https://doi.org/10.1007/s10620-023-08180-0
Haastrup, P. F., Jarbøl, D. E., Thompson, W., Hansen, J. M., Søndergaard, J., & Rasmussen, S. (2021). When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterology, 8(1). https://doi.org/10.1136/bmjgast-2020-000563
Hamada, K., Irisawa, A., Horikawa, Y., Shiwa, Y., Techigawara, K., Ishikawa, M., Nagahashi, T., Fukushima, D., Nishino, N., Sakuma, H., & Honda, M. (2023). Neuroendocrine tumor of the ampulla of Vater treated with endoscopic papillectomy: A case report. DEN Open, 3(1), e191. https://doi.org/10.1002/deo2.191
Hope, T. A., Abbott, A., Colucci, K., Bushnell, D. L., Gardner, L., Graham, W. S., Lindsay, S., Metz, D. C., Pryma, D. A., Stabin, M. G., & Strosberg, J. R. (2019). NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 60(7), 937–943. https://doi.org/10.2967/jnumed.118.230607
Huang, S.-F., Kuo, I.-M., Lee, C.-W., Pan, K.-T., Chen, T.-C., Lin, C.-J., Hwang, T.-L., & Yu, M.-C. (2015). Comparison study of gastrinomas between gastric and non-gastric origins. World Journal of Surgical Oncology, 13, 202. https://doi.org/10.1186/s12957-015-0614-6
Hutchinson, L. (2014). Neuroendocrine cancer: CLARINET: new option for NETS. Nature Reviews. Endocrinology, 10(10), 577. https://doi.org/10.1038/nrendo.2014.133
Kaliszewski, K., Ludwig, M., Greniuk, M., Mikuła, A., Zagórski, K., & Rudnicki, J. (2022). Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Cancers, 14(8). https://doi.org/10.3390/cancers14082028
Kidd, M., & Gustafsson, B. I. (2012). Management of gastric carcinoids (neuroendocrine neoplasms). Current Gastroenterology Reports, 14(6), 467–472. https://doi.org/10.1007/s11894-012-0289-x
Kitay, A. M., Schneebacher, M.-T., Schmitt, A., Heschl, K., Kopic, S., Alfadda, T., Alsaihati, A., Link, A., & Geibel, J. P. (2018). Modulations in extracellular calcium lead to H(+)-ATPase-dependent acid secretion: a clarification of PPI failure. American Journal of Physiology. Gastrointestinal and Liver Physiology, 315(1), G36–G42. https://doi.org/10.1152/ajpgi.00132.2017
Klöppel, G. (2011). Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocrine-Related Cancer, 18 Suppl 1, S1-16. https://doi.org/10.1530/ERC-11-0013
Klöppel, G., Rindi, G., Perren, A., Komminoth, P., & Klimstra, D. S. (2010). The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. In Virchows Archiv : an international journal of pathology (Vol. 456, Issue 6, pp. 595–597). https://doi.org/10.1007/s00428-010-0924-6
Kobayashi, N., Takano, S., Ito, K., Sugiura, M., Ogawa, M., Takeda, Y., Okubo, N., Suzuki, A., Tokuhisa, M., Kaneta, T., Utsunomiya, D., Hata, M., Inoue, T., Hosono, M., Kinuya, S., & Ichikawa, Y. (2021). Safety and efficacy of peptide receptor radionuclide therapy with (177)Lu-DOTA(0)-Tyr(3)-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors. Annals of Nuclear Medicine, 35(12), 1332–1341. https://doi.org/10.1007/s12149-021-01674-9
Komarnicki, P., Musiałkiewicz, J., Stańska, A., Maciejewski, A., Gut, P., Mastorakos, G., & Ruchała, M. (2022). Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future. Journal of Clinical Medicine, 11(19). https://doi.org/10.3390/jcm11195542
Kong, L., Yan, C., Nie, S., Jin, H., & Li, X. (2024). Comparison of proximal and distal gastric neuroendocrine carcinoma based on SEER database. Scientific Reports, 14(1), 25956. https://doi.org/10.1038/s41598-024-76689-z
Krieg, S., Roderburg, C., Fung, S., Luedde, T., Knoefel, W. T., & Krieg, A. (2022). Nuclear survivin is a prognosticator in gastroenteropancreatic neuroendocrine neoplasms: a meta-analysis. Journal of Cancer Research and Clinical Oncology, 148(9), 2235–2246. https://doi.org/10.1007/s00432-022-04013-1
Kulkarni, H. R., Schuchardt, C., & Baum, R. P. (2013). Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer, 194, 551–559. https://doi.org/10.1007/978-3-642-27994-2_32
Kulke, M. H., Anthony, L. B., Bushnell, D. L., de Herder, W. W., Goldsmith, S. J., Klimstra, D. S., Marx, S. J., Pasieka, J. L., Pommier, R. F., Yao, J. C., & Jensen, R. T. (2010). NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas, 39(6), 735–752. https://doi.org/10.1097/MPA.0b013e3181ebb168
Kunz, P. L., Reidy-Lagunes, D., Anthony, L. B., Bertino, E. M., Brendtro, K., Chan, J. A., Chen, H., Jensen, R. T., Kim, M. K., Klimstra, D. S., Kulke, M. H., Liu, E. H., Metz, D. C., Phan, A. T., Sippel, R. S., Strosberg, J. R., & Yao, J. C. (2013). Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas, 42(4), 557–577. https://doi.org/10.1097/MPA.0b013e31828e34a4
Lawrence, B., Gustafsson, B. I., Chan, A., Svejda, B., Kidd, M., & Modlin, I. M. (2011). The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America, 40(1), 1–18, vii. https://doi.org/10.1016/j.ecl.2010.12.005
Liu, E. H., Solorzano, C. C., Katznelson, L., Vinik, A. I., Wong, R., & Randolph, G. (2015). AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 21(5), 534–545. https://doi.org/10.4158/EP14464.DSC
Liu, K. Y., Goldrich, D. Y., Ninan, S. J., Filimonov, A., Lam, H., Govindaraj, S., & Iloreta, A. M. (2021). The value of (68) Gallium-DOTATATE PET/CT in sinonasal neuroendocrine tumor management: A case series. Head & Neck, 43(6), E30–E40. https://doi.org/10.1002/hed.26695
Nagao, S., Yabuuchi, Y., Tanaka, K., Morihisa, Y., Kobayashi, T., Akiyama, S., Tanke, G., Wada, M., Morita, S., Inoue, S., Hobyung, C., Yamashita, D., & Inokuma, T. (2024). Multiple Gastric Neuroendocrine Tumors Associated with Long-term Use of a Proton Pump Inhibitor and a Potassium-competitive Acid Blocker. Internal Medicine (Tokyo, Japan), 63(14), 2001–2010. https://doi.org/10.2169/internalmedicine.2857-23
Nikou, G. C., Toubanakis, C., Moulakakis, K. G., Pavlatos, S., Kosmidis, C., Mallas, E., Safioleas, P., Sakorafas, G. H., & Safioleas, M. C. (2011). Carcinoid tumors of the duodenum and the ampulla of Vater: current diagnostic and therapeutic approach in a series of 8 patients. Case series. International Journal of Surgery (London, England), 9(3), 248–253. https://doi.org/10.1016/j.ijsu.2010.12.003
Nobels, F. R., Kwekkeboom, D. J., Coopmans, W., Schoenmakers, C. H., Lindemans, J., De Herder, W. W., Krenning, E. P., Bouillon, R., & Lamberts, S. W. (1997). Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. The Journal of Clinical Endocrinology and Metabolism, 82(8), 2622–2628. https://doi.org/10.1210/jcem.82.8.4145
Ohlsson, H., Gålne, A., Trägårdh, E., Malmström, M., Sundlöv, A., & Almquist, M. (2022). Relationship between somatostatin receptor expressing tumour volume and health-related quality of life in patients with metastatic GEP-NET. Journal of Neuroendocrinology, 34(6), e13139. https://doi.org/10.1111/jne.13139
Pak, L. M., Yang, T., & Wang, J. (2019). Further Classification for Node-Positive Gastric Neuroendocrine Neoplasms. Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract, 23(4), 720–729. https://doi.org/10.1007/s11605-018-3845-3
Panzuto, F., Magi, L., Esposito, G., Rinzivillo, M., & Annibale, B. (2021). Comparison of Endoscopic Techniques in the Management of Type I Gastric Neuroendocrine Neoplasia: A Systematic Review. Gastroenterology Research and Practice, 2021, 6679397. https://doi.org/10.1155/2021/6679397
Panzuto, F., Ramage, J., Pritchard, D. M., van Velthuysen, M.-L. F., Schrader, J., Begum, N., Sundin, A., Falconi, M., & O’Toole, D. (2023). European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3. Journal of Neuroendocrinology, 35(8), e13306. https://doi.org/10.1111/jne.13306
Pavel, M. E., Hainsworth, J. D., Baudin, E., Peeters, M., Hörsch, D., Winkler, R. E., Klimovsky, J., Lebwohl, D., Jehl, V., Wolin, E. M., Öberg, K., Van Cutsem, E., & Yao, J. C. (2011). Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet, 378(9808), 2005–2012. https://doi.org/10.1016/S0140-6736(11)61742-X
Pawlik, T. M. (2020). Management of Gastrointestinal and Pancreatic Neuroendocrine Tumors. In Surgical oncology clinics of North America (Vol. 29, Issue 2, pp. xiii–xiv). https://doi.org/10.1016/j.soc.2020.02.001
Pellegrino, F., Granata, V., Fusco, R., Grassi, F., Tafuto, S., Perrucci, L., Tralli, G., & Scaglione, M. (2023). Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists. Tomography (Ann Arbor, Mich.), 9(1), 217–246. https://doi.org/10.3390/tomography9010018
Pyun, D.-K., Moon, G., Han, J., Kim, M.-H., Lee, S. S., Seo, D.-W., & Lee, S.-K. (2004). A carcinoid tumor of the ampulla of Vater treated by endoscopic snare papillectomy. The Korean Journal of Internal Medicine, 19(4), 257–260. https://doi.org/10.3904/kjim.2004.19.4.257
Rinke, A., Wittenberg, M., Schade-Brittinger, C., Aminossadati, B., Ronicke, E., Gress, T. M., Müller, H.-H., & Arnold, R. (2017). Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. Neuroendocrinology, 104(1), 26–32. https://doi.org/10.1159/000443612
Sachs, G., Shin, J. M., Vagin, O., Lambrecht, N., Yakubov, I., & Munson, K. (2007). The gastric H,K ATPase as a drug target: past, present, and future. Journal of Clinical Gastroenterology, 41 Suppl 2(Suppl 2), S226-42. https://doi.org/10.1097/MCG.0b013e31803233b7
Sadowski, S. M., Millo, C., Cottle-Delisle, C., Merkel, R., Yang, L. A., Herscovitch, P., Pacak, K., Simonds, W. F., Marx, S. J., & Kebebew, E. (2015). Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1. Journal of the American College of Surgeons, 221(2), 509–517. https://doi.org/10.1016/j.jamcollsurg.2015.04.005
Sato, Y., Hashimoto, S., Mizuno, K.-I., Takeuchi, M., & Terai, S. (2016). Management of gastric and duodenal neuroendocrine tumors. World Journal of Gastroenterology, 22(30), 6817–6828. https://doi.org/10.3748/wjg.v22.i30.6817
Shah, S. C., Piazuelo, M. B., Kuipers, E. J., & Li, D. (2021). AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review. Gastroenterology, 161(4), 1325-1332.e7. https://doi.org/10.1053/j.gastro.2021.06.078
Singh, S., Halperin, D., Myrehaug, S., Herrmann, K., Pavel, M., Kunz, P. L., Chasen, B., Tafuto, S., Lastoria, S., Capdevila, J., García-Burillo, A., Oh, D.-Y., Yoo, C., Halfdanarson, T. R., Falk, S., Folitar, I., Zhang, Y., Aimone, P., de Herder, W. W., & Ferone, D. (2024). [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, p. Lancet, 403(10446), 2807–2817. https://doi.org/10.1016/S0140-6736(24)00701-3
Singla, S., LeVea, C. M., Pokuri, V. K., Attwood, K. M., Wach, M. M., Tomaszewski, G. M., Kuvshinoff, B., & Iyer, R. (2016). Ki67 score as a potential predictor in the selection of liver-directed therapies for metastatic neuroendocrine tumors: a single institutional experience. Journal of Gastrointestinal Oncology, 7(3), 441–448. https://doi.org/10.21037/jgo.2016.02.02
Sok, C., & Shah, M. M. (2024). ASO Author Reflections: Simplifying the Fundamentals of Gastric Neuroendocrine Tumor Management. Annals of Surgical Oncology, 31(3), 1519–1520. https://doi.org/10.1245/s10434-023-14820-6
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., Bushnell, D., O’Dorisio, T. M., Baum, R. P., Kulkarni, H. R., Caplin, M., Lebtahi, R., Hobday, T., Delpassand, E., Van Cutsem, E., … Krenning, E. (2017). Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. The New England Journal of Medicine, 376(2), 125–135. https://doi.org/10.1056/NEJMoa1607427
Strosberg, J. R., Yao, J. C., Bajetta, E., Aout, M., Bakker, B., Hainsworth, J. D., Ruszniewski, P. B., Van Cutsem, E., Öberg, K., & Pavel, M. E. (2015). Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis. Endocrine-Related Cancer, 22(6), 933–940. https://doi.org/10.1530/ERC-15-0314
Tomassetti, P., Migliori, M., Caletti, G. C., Fusaroli, P., Corinaldesi, R., & Gullo, L. (2000). Treatment of type II gastric carcinoid tumors with somatostatin analogues. The New England Journal of Medicine, 343(8), 551–554. https://doi.org/10.1056/NEJM200008243430805
Tsoucalas, G., Karamanou, M., & Androutsos, G. (2011). The eminent German pathologist Siegfried Oberndorfer (1876-1944) and his landmark work on carcinoid tumors. Annals of Gastroenterology, 24(2), 98–100. pmid:24713679
Tsuboi, M., Niikura, R., Hayakawa, Y., Hirata, Y., Ushiku, T., & Koike, K. (2020). Distinct Features of Autoimmune Gastritis in Patients with Open-Type Chronic Gastritis in Japan. Biomedicines, 8(10). https://doi.org/10.3390/biomedicines8100419
Vannella, L., Lahner, E., & Annibale, B. (2012). Risk for gastric neoplasias in patients with chronic atrophic gastritis: a critical reappraisal. In World journal of gastroenterology (Vol. 18, Issue 12, pp. 1279–1285). https://doi.org/10.3748/wjg.v18.i12.1279
Vanoli, A., La Rosa, S., Miceli, E., Klersy, C., Maragliano, R., Capuano, F., Persichella, A., Martino, M., Inzani, F., Luinetti, O., Di Sabatino, A., Sessa, F., Paulli, M., Corazza, G. R., Rindi, G., Bordi, C., Capella, C., & Solcia, E. (2018). Prognostic Evaluations Tailored to Specific Gastric Neuroendocrine Neoplasms: Analysis Of 200 Cases with Extended Follow-Up. Neuroendocrinology, 107(2), 114–126. https://doi.org/10.1159/000489902
Woltering, E. A., Wright, A. E., Stevens, M. A., Wang, Y.-Z., Boudreaux, J. P., Mamikunian, G., Riopelle, J. M., & Kaye, A. D. (2016). Development of effective prophylaxis against intraoperative carcinoid crisis. Journal of Clinical Anesthesia, 32, 189–193. https://doi.org/10.1016/j.jclinane.2016.03.008
Wu, Z., Shang, G., Zhang, K., Wang, W., Fan, M., & Lin, R. (2024). A nomogram incorporating treatment data for predicting overall survival in gastroenteropancreatic neuroendocrine tumors: a population-based cohort study. International Journal of Surgery (London, England), 110(4), 2178–2186. https://doi.org/10.1097/JS9.0000000000001080
Xu, Z., Wang, L., Dai, S., Chen, M., Li, F., Sun, J., & Luo, F. (2021). Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States. JAMA Network Open, 4(9), e2124750. https://doi.org/10.1001/jamanetworkopen.2021.24750
Yang, M., Zeng, L., Zhang, Y., Wang, W.-G., Wang, L., Ke, N.-W., Liu, X.-B., & Tian, B. (2015). TNM staging of pancreatic neuroendocrine tumors: an observational analysis and comparison by both AJCC and ENETS systems from 1 single institution. Medicine, 94(12), e660. https://doi.org/10.1097/MD.0000000000000660
Yao, J. C., Phan, A. T., Chang, D. Z., Wolff, R. A., Hess, K., Gupta, S., Jacobs, C., Mares, J. E., Landgraf, A. N., Rashid, A., & Meric-Bernstam, F. (2008). Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 26(26), 4311–4318. https://doi.org/10.1200/JCO.2008.16.7858
Zhou, X.-P., Sun, L.-B., Liu, W.-H., Song, X.-Y., Gao, Y., Xing, J.-P., & Gao, S.-H. (2025). Development and validation of predictive models for distant metastasis and prognosis of gastroenteropancreatic neuroendocrine neoplasms. Scientific Reports, 15(1), 9510. https://doi.org/10.1038/s41598-025-92974-x
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017). The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. In CA: a cancer journal for clinicians (Vol. 67, Issue 2, pp. 93–99). https://doi.org/10.3322/caac.21388
Ammann, M., Kinney, M. A. O., Gudmundsdottir, H., Santol, J., Thiels, C. A., Warner, S. G., Truty, M. J., Kendrick, M. L., Smoot, R. L., Anderson, A. L., Halfdanarson, T. R., Nagorney, D. M., & Starlinger, P. P. (2024). Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis. In Annals of surgical oncology (Vol. 31, Issue 6, pp. 3976–3977). https://doi.org/10.1245/s10434-024-15264-2
Campana, D., Ravizza, D., Ferolla, P., Faggiano, A., Grimaldi, F., Albertelli, M., Ricci, C., Santini, D., Brighi, N., Fazio, N., Colao, A., Ferone, D., & Tomassetti, P. (2017). Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. Endocrine, 56(3), 633–638. https://doi.org/10.1007/s12020-016-1099-y
Caplin, M. E., Pavel, M., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L., Rindi, G., Langley, A., Martinez, S., Blumberg, J., & Ruszniewski, P. (2014). Lanreotide in metastatic enteropancreatic neuroendocrine tumors. The New England Journal of Medicine, 371(3), 224–233. https://doi.org/10.1056/NEJMoa1316158
Castillo, J. G., Filsoufi, F., Adams, D. H., Raikhelkar, J., Zaku, B., & Fischer, G. W. (2008). Management of patients undergoing multivalvular surgery for carcinoid heart disease: the role of the anaesthetist. British Journal of Anaesthesia, 101(5), 618–626. https://doi.org/10.1093/bja/aen237
Choi, C. K. (2014). Anesthetic considerations and management of a patient with unsuspected carcinoid crisis during hepatic tumor resection. Middle East Journal of Anaesthesiology, 22(5), 515–518.
Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., & Xu, Y. (2017). Trends in the Incidence , Prevalence , and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncology, 3(10), 1–2. https://doi.org/10.1001/jamaoncol.2017.0589
Dasari, A., Wallace, K., Halperin, D. M., Maxwell, J., Kunz, P., Singh, S., Chasen, B., & Yao, J. C. (2025). Epidemiology of Neuroendocrine Neoplasms in the US. JAMA Network Open, 8(6), e2515798. https://doi.org/10.1001/jamanetworkopen.2025.15798
Dell’Unto, E., Esposito, G., Rinzivillo, M., Marasco, M., Annibale, B., & Panzuto, F. (2024). Type 3 gastric neuroendocrine neoplasms: the rising promise of conservative endoscopic management. Frontiers in Medicine, 11, 1327864. https://doi.org/10.3389/fmed.2024.1327864
Delle Fave, G., O’Toole, D., Sundin, A., Taal, B., Ferolla, P., Ramage, J. K., Ferone, D., Ito, T., Weber, W., Zheng-Pei, Z., De Herder, W. W., Pascher, A., & Ruszniewski, P. (2016). ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology, 103(2), 119–124. https://doi.org/10.1159/000443168
Eads, J. R., Halfdanarson, T. R., Asmis, T., Bellizzi, A. M., Bergsland, E. K., Dasari, A., El-Haddad, G., Frumovitz, M., Meyer, J., Mittra, E., Myrehaug, S., Nakakura, E., Raj, N., Soares, H. P., Untch, B., Vijayvergia, N., & Chan, J. A. (2023). Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Endocrine-Related Cancer, 30(8). https://doi.org/10.1530/ERC-22-0206
Engevik, A. C., Kaji, I., & Goldenring, J. R. (2020). The Physiology of the Gastric Parietal Cell. Physiological Reviews, 100(2), 573–602. https://doi.org/10.1152/physrev.00016.2019
Exarchou, K., Kamieniarz, L., Tsoli, M., Victor, A., Oleinikov, K., Khan, M. S., Srirajaskanthan, R., Mandair, D., Grozinsky-Glasberg, S., Kaltsas, G., Howes, N., Pritchard, D. M., & Toumpanakis, C. (2021). Is local excision sufficient in selected grade 1 or 2 type III gastric neuroendocrine neoplasms? Endocrine, 74(2), 421–429. https://doi.org/10.1007/s12020-021-02775-1
Exarchou, K., Stephens, N. A., Moore, A. R., Howes, N. R., & Pritchard, D. M. (2022). New Developments in Gastric Neuroendocrine Neoplasms. Current Oncology Reports, 24(1), 77–88. https://doi.org/10.1007/s11912-021-01175-y
Fang, C., Wang, W., Feng, X., Sun, J., Zhang, Y., Zeng, Y., Wang, J., Chen, H., Cai, M., Lin, J., Chen, M., Chen, Y., Li, Y., Li, S., Chen, J., & Zhou, Z. (2017). Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. British Journal of Cancer, 117(10), 1544–1550. https://doi.org/10.1038/bjc.2017.315
Felder, S., Jann, H., Arsenic, R., Denecke, T., Prasad, V., Knappe-Drzikova, B., Maasberg, S., Wiedenmann, B., Pavel, M., Pascher, A., & Pape, U. F. (2019). Gastric neuroendocrine neoplasias: manifestations and comparative outcomes. Endocrine-Related Cancer, 26(9), 751–763. https://doi.org/10.1530/ERC-18-0582
Guo, X., Zhao, X., Huang, G., & Yu, Y. (2024). Advances in Endoscopic Diagnosis and Treatment of Gastric Neuroendocrine Neoplasms. Digestive Diseases and Sciences, 69(1), 27–35. https://doi.org/10.1007/s10620-023-08180-0
Haastrup, P. F., Jarbøl, D. E., Thompson, W., Hansen, J. M., Søndergaard, J., & Rasmussen, S. (2021). When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterology, 8(1). https://doi.org/10.1136/bmjgast-2020-000563
Hamada, K., Irisawa, A., Horikawa, Y., Shiwa, Y., Techigawara, K., Ishikawa, M., Nagahashi, T., Fukushima, D., Nishino, N., Sakuma, H., & Honda, M. (2023). Neuroendocrine tumor of the ampulla of Vater treated with endoscopic papillectomy: A case report. DEN Open, 3(1), e191. https://doi.org/10.1002/deo2.191
Hope, T. A., Abbott, A., Colucci, K., Bushnell, D. L., Gardner, L., Graham, W. S., Lindsay, S., Metz, D. C., Pryma, D. A., Stabin, M. G., & Strosberg, J. R. (2019). NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 60(7), 937–943. https://doi.org/10.2967/jnumed.118.230607
Huang, S.-F., Kuo, I.-M., Lee, C.-W., Pan, K.-T., Chen, T.-C., Lin, C.-J., Hwang, T.-L., & Yu, M.-C. (2015). Comparison study of gastrinomas between gastric and non-gastric origins. World Journal of Surgical Oncology, 13, 202. https://doi.org/10.1186/s12957-015-0614-6
Hutchinson, L. (2014). Neuroendocrine cancer: CLARINET: new option for NETS. Nature Reviews. Endocrinology, 10(10), 577. https://doi.org/10.1038/nrendo.2014.133
Kaliszewski, K., Ludwig, M., Greniuk, M., Mikuła, A., Zagórski, K., & Rudnicki, J. (2022). Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Cancers, 14(8). https://doi.org/10.3390/cancers14082028
Kidd, M., & Gustafsson, B. I. (2012). Management of gastric carcinoids (neuroendocrine neoplasms). Current Gastroenterology Reports, 14(6), 467–472. https://doi.org/10.1007/s11894-012-0289-x
Kitay, A. M., Schneebacher, M.-T., Schmitt, A., Heschl, K., Kopic, S., Alfadda, T., Alsaihati, A., Link, A., & Geibel, J. P. (2018). Modulations in extracellular calcium lead to H(+)-ATPase-dependent acid secretion: a clarification of PPI failure. American Journal of Physiology. Gastrointestinal and Liver Physiology, 315(1), G36–G42. https://doi.org/10.1152/ajpgi.00132.2017
Klöppel, G. (2011). Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocrine-Related Cancer, 18 Suppl 1, S1-16. https://doi.org/10.1530/ERC-11-0013
Klöppel, G., Rindi, G., Perren, A., Komminoth, P., & Klimstra, D. S. (2010). The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. In Virchows Archiv : an international journal of pathology (Vol. 456, Issue 6, pp. 595–597). https://doi.org/10.1007/s00428-010-0924-6
Kobayashi, N., Takano, S., Ito, K., Sugiura, M., Ogawa, M., Takeda, Y., Okubo, N., Suzuki, A., Tokuhisa, M., Kaneta, T., Utsunomiya, D., Hata, M., Inoue, T., Hosono, M., Kinuya, S., & Ichikawa, Y. (2021). Safety and efficacy of peptide receptor radionuclide therapy with (177)Lu-DOTA(0)-Tyr(3)-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors. Annals of Nuclear Medicine, 35(12), 1332–1341. https://doi.org/10.1007/s12149-021-01674-9
Komarnicki, P., Musiałkiewicz, J., Stańska, A., Maciejewski, A., Gut, P., Mastorakos, G., & Ruchała, M. (2022). Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future. Journal of Clinical Medicine, 11(19). https://doi.org/10.3390/jcm11195542
Kong, L., Yan, C., Nie, S., Jin, H., & Li, X. (2024). Comparison of proximal and distal gastric neuroendocrine carcinoma based on SEER database. Scientific Reports, 14(1), 25956. https://doi.org/10.1038/s41598-024-76689-z
Krieg, S., Roderburg, C., Fung, S., Luedde, T., Knoefel, W. T., & Krieg, A. (2022). Nuclear survivin is a prognosticator in gastroenteropancreatic neuroendocrine neoplasms: a meta-analysis. Journal of Cancer Research and Clinical Oncology, 148(9), 2235–2246. https://doi.org/10.1007/s00432-022-04013-1
Kulkarni, H. R., Schuchardt, C., & Baum, R. P. (2013). Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer, 194, 551–559. https://doi.org/10.1007/978-3-642-27994-2_32
Kulke, M. H., Anthony, L. B., Bushnell, D. L., de Herder, W. W., Goldsmith, S. J., Klimstra, D. S., Marx, S. J., Pasieka, J. L., Pommier, R. F., Yao, J. C., & Jensen, R. T. (2010). NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas, 39(6), 735–752. https://doi.org/10.1097/MPA.0b013e3181ebb168
Kunz, P. L., Reidy-Lagunes, D., Anthony, L. B., Bertino, E. M., Brendtro, K., Chan, J. A., Chen, H., Jensen, R. T., Kim, M. K., Klimstra, D. S., Kulke, M. H., Liu, E. H., Metz, D. C., Phan, A. T., Sippel, R. S., Strosberg, J. R., & Yao, J. C. (2013). Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas, 42(4), 557–577. https://doi.org/10.1097/MPA.0b013e31828e34a4
Lawrence, B., Gustafsson, B. I., Chan, A., Svejda, B., Kidd, M., & Modlin, I. M. (2011). The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America, 40(1), 1–18, vii. https://doi.org/10.1016/j.ecl.2010.12.005
Liu, E. H., Solorzano, C. C., Katznelson, L., Vinik, A. I., Wong, R., & Randolph, G. (2015). AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 21(5), 534–545. https://doi.org/10.4158/EP14464.DSC
Liu, K. Y., Goldrich, D. Y., Ninan, S. J., Filimonov, A., Lam, H., Govindaraj, S., & Iloreta, A. M. (2021). The value of (68) Gallium-DOTATATE PET/CT in sinonasal neuroendocrine tumor management: A case series. Head & Neck, 43(6), E30–E40. https://doi.org/10.1002/hed.26695
Nagao, S., Yabuuchi, Y., Tanaka, K., Morihisa, Y., Kobayashi, T., Akiyama, S., Tanke, G., Wada, M., Morita, S., Inoue, S., Hobyung, C., Yamashita, D., & Inokuma, T. (2024). Multiple Gastric Neuroendocrine Tumors Associated with Long-term Use of a Proton Pump Inhibitor and a Potassium-competitive Acid Blocker. Internal Medicine (Tokyo, Japan), 63(14), 2001–2010. https://doi.org/10.2169/internalmedicine.2857-23
Nikou, G. C., Toubanakis, C., Moulakakis, K. G., Pavlatos, S., Kosmidis, C., Mallas, E., Safioleas, P., Sakorafas, G. H., & Safioleas, M. C. (2011). Carcinoid tumors of the duodenum and the ampulla of Vater: current diagnostic and therapeutic approach in a series of 8 patients. Case series. International Journal of Surgery (London, England), 9(3), 248–253. https://doi.org/10.1016/j.ijsu.2010.12.003
Nobels, F. R., Kwekkeboom, D. J., Coopmans, W., Schoenmakers, C. H., Lindemans, J., De Herder, W. W., Krenning, E. P., Bouillon, R., & Lamberts, S. W. (1997). Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. The Journal of Clinical Endocrinology and Metabolism, 82(8), 2622–2628. https://doi.org/10.1210/jcem.82.8.4145
Ohlsson, H., Gålne, A., Trägårdh, E., Malmström, M., Sundlöv, A., & Almquist, M. (2022). Relationship between somatostatin receptor expressing tumour volume and health-related quality of life in patients with metastatic GEP-NET. Journal of Neuroendocrinology, 34(6), e13139. https://doi.org/10.1111/jne.13139
Pak, L. M., Yang, T., & Wang, J. (2019). Further Classification for Node-Positive Gastric Neuroendocrine Neoplasms. Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract, 23(4), 720–729. https://doi.org/10.1007/s11605-018-3845-3
Panzuto, F., Magi, L., Esposito, G., Rinzivillo, M., & Annibale, B. (2021). Comparison of Endoscopic Techniques in the Management of Type I Gastric Neuroendocrine Neoplasia: A Systematic Review. Gastroenterology Research and Practice, 2021, 6679397. https://doi.org/10.1155/2021/6679397
Panzuto, F., Ramage, J., Pritchard, D. M., van Velthuysen, M.-L. F., Schrader, J., Begum, N., Sundin, A., Falconi, M., & O’Toole, D. (2023). European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3. Journal of Neuroendocrinology, 35(8), e13306. https://doi.org/10.1111/jne.13306
Pavel, M. E., Hainsworth, J. D., Baudin, E., Peeters, M., Hörsch, D., Winkler, R. E., Klimovsky, J., Lebwohl, D., Jehl, V., Wolin, E. M., Öberg, K., Van Cutsem, E., & Yao, J. C. (2011). Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet, 378(9808), 2005–2012. https://doi.org/10.1016/S0140-6736(11)61742-X
Pawlik, T. M. (2020). Management of Gastrointestinal and Pancreatic Neuroendocrine Tumors. In Surgical oncology clinics of North America (Vol. 29, Issue 2, pp. xiii–xiv). https://doi.org/10.1016/j.soc.2020.02.001
Pellegrino, F., Granata, V., Fusco, R., Grassi, F., Tafuto, S., Perrucci, L., Tralli, G., & Scaglione, M. (2023). Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists. Tomography (Ann Arbor, Mich.), 9(1), 217–246. https://doi.org/10.3390/tomography9010018
Pyun, D.-K., Moon, G., Han, J., Kim, M.-H., Lee, S. S., Seo, D.-W., & Lee, S.-K. (2004). A carcinoid tumor of the ampulla of Vater treated by endoscopic snare papillectomy. The Korean Journal of Internal Medicine, 19(4), 257–260. https://doi.org/10.3904/kjim.2004.19.4.257
Rinke, A., Wittenberg, M., Schade-Brittinger, C., Aminossadati, B., Ronicke, E., Gress, T. M., Müller, H.-H., & Arnold, R. (2017). Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. Neuroendocrinology, 104(1), 26–32. https://doi.org/10.1159/000443612
Sachs, G., Shin, J. M., Vagin, O., Lambrecht, N., Yakubov, I., & Munson, K. (2007). The gastric H,K ATPase as a drug target: past, present, and future. Journal of Clinical Gastroenterology, 41 Suppl 2(Suppl 2), S226-42. https://doi.org/10.1097/MCG.0b013e31803233b7
Sadowski, S. M., Millo, C., Cottle-Delisle, C., Merkel, R., Yang, L. A., Herscovitch, P., Pacak, K., Simonds, W. F., Marx, S. J., & Kebebew, E. (2015). Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1. Journal of the American College of Surgeons, 221(2), 509–517. https://doi.org/10.1016/j.jamcollsurg.2015.04.005
Sato, Y., Hashimoto, S., Mizuno, K.-I., Takeuchi, M., & Terai, S. (2016). Management of gastric and duodenal neuroendocrine tumors. World Journal of Gastroenterology, 22(30), 6817–6828. https://doi.org/10.3748/wjg.v22.i30.6817
Shah, S. C., Piazuelo, M. B., Kuipers, E. J., & Li, D. (2021). AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review. Gastroenterology, 161(4), 1325-1332.e7. https://doi.org/10.1053/j.gastro.2021.06.078
Singh, S., Halperin, D., Myrehaug, S., Herrmann, K., Pavel, M., Kunz, P. L., Chasen, B., Tafuto, S., Lastoria, S., Capdevila, J., García-Burillo, A., Oh, D.-Y., Yoo, C., Halfdanarson, T. R., Falk, S., Folitar, I., Zhang, Y., Aimone, P., de Herder, W. W., & Ferone, D. (2024). [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, p. Lancet, 403(10446), 2807–2817. https://doi.org/10.1016/S0140-6736(24)00701-3
Singla, S., LeVea, C. M., Pokuri, V. K., Attwood, K. M., Wach, M. M., Tomaszewski, G. M., Kuvshinoff, B., & Iyer, R. (2016). Ki67 score as a potential predictor in the selection of liver-directed therapies for metastatic neuroendocrine tumors: a single institutional experience. Journal of Gastrointestinal Oncology, 7(3), 441–448. https://doi.org/10.21037/jgo.2016.02.02
Sok, C., & Shah, M. M. (2024). ASO Author Reflections: Simplifying the Fundamentals of Gastric Neuroendocrine Tumor Management. Annals of Surgical Oncology, 31(3), 1519–1520. https://doi.org/10.1245/s10434-023-14820-6
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., Bushnell, D., O’Dorisio, T. M., Baum, R. P., Kulkarni, H. R., Caplin, M., Lebtahi, R., Hobday, T., Delpassand, E., Van Cutsem, E., … Krenning, E. (2017). Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. The New England Journal of Medicine, 376(2), 125–135. https://doi.org/10.1056/NEJMoa1607427
Strosberg, J. R., Yao, J. C., Bajetta, E., Aout, M., Bakker, B., Hainsworth, J. D., Ruszniewski, P. B., Van Cutsem, E., Öberg, K., & Pavel, M. E. (2015). Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis. Endocrine-Related Cancer, 22(6), 933–940. https://doi.org/10.1530/ERC-15-0314
Tomassetti, P., Migliori, M., Caletti, G. C., Fusaroli, P., Corinaldesi, R., & Gullo, L. (2000). Treatment of type II gastric carcinoid tumors with somatostatin analogues. The New England Journal of Medicine, 343(8), 551–554. https://doi.org/10.1056/NEJM200008243430805
Tsoucalas, G., Karamanou, M., & Androutsos, G. (2011). The eminent German pathologist Siegfried Oberndorfer (1876-1944) and his landmark work on carcinoid tumors. Annals of Gastroenterology, 24(2), 98–100. pmid:24713679
Tsuboi, M., Niikura, R., Hayakawa, Y., Hirata, Y., Ushiku, T., & Koike, K. (2020). Distinct Features of Autoimmune Gastritis in Patients with Open-Type Chronic Gastritis in Japan. Biomedicines, 8(10). https://doi.org/10.3390/biomedicines8100419
Vannella, L., Lahner, E., & Annibale, B. (2012). Risk for gastric neoplasias in patients with chronic atrophic gastritis: a critical reappraisal. In World journal of gastroenterology (Vol. 18, Issue 12, pp. 1279–1285). https://doi.org/10.3748/wjg.v18.i12.1279
Vanoli, A., La Rosa, S., Miceli, E., Klersy, C., Maragliano, R., Capuano, F., Persichella, A., Martino, M., Inzani, F., Luinetti, O., Di Sabatino, A., Sessa, F., Paulli, M., Corazza, G. R., Rindi, G., Bordi, C., Capella, C., & Solcia, E. (2018). Prognostic Evaluations Tailored to Specific Gastric Neuroendocrine Neoplasms: Analysis Of 200 Cases with Extended Follow-Up. Neuroendocrinology, 107(2), 114–126. https://doi.org/10.1159/000489902
Woltering, E. A., Wright, A. E., Stevens, M. A., Wang, Y.-Z., Boudreaux, J. P., Mamikunian, G., Riopelle, J. M., & Kaye, A. D. (2016). Development of effective prophylaxis against intraoperative carcinoid crisis. Journal of Clinical Anesthesia, 32, 189–193. https://doi.org/10.1016/j.jclinane.2016.03.008
Wu, Z., Shang, G., Zhang, K., Wang, W., Fan, M., & Lin, R. (2024). A nomogram incorporating treatment data for predicting overall survival in gastroenteropancreatic neuroendocrine tumors: a population-based cohort study. International Journal of Surgery (London, England), 110(4), 2178–2186. https://doi.org/10.1097/JS9.0000000000001080
Xu, Z., Wang, L., Dai, S., Chen, M., Li, F., Sun, J., & Luo, F. (2021). Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States. JAMA Network Open, 4(9), e2124750. https://doi.org/10.1001/jamanetworkopen.2021.24750
Yang, M., Zeng, L., Zhang, Y., Wang, W.-G., Wang, L., Ke, N.-W., Liu, X.-B., & Tian, B. (2015). TNM staging of pancreatic neuroendocrine tumors: an observational analysis and comparison by both AJCC and ENETS systems from 1 single institution. Medicine, 94(12), e660. https://doi.org/10.1097/MD.0000000000000660
Yao, J. C., Phan, A. T., Chang, D. Z., Wolff, R. A., Hess, K., Gupta, S., Jacobs, C., Mares, J. E., Landgraf, A. N., Rashid, A., & Meric-Bernstam, F. (2008). Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 26(26), 4311–4318. https://doi.org/10.1200/JCO.2008.16.7858
Zhou, X.-P., Sun, L.-B., Liu, W.-H., Song, X.-Y., Gao, Y., Xing, J.-P., & Gao, S.-H. (2025). Development and validation of predictive models for distant metastasis and prognosis of gastroenteropancreatic neuroendocrine neoplasms. Scientific Reports, 15(1), 9510. https://doi.org/10.1038/s41598-025-92974-x
Publicado
2026-01-30
Cómo citar
Arzuza Torres, B. J., Bautista Bedoya, J. M., Cabrera Salgado, R. A., Lectamo Caicedo , L., Estupiñan Alegría, K. N., & Andrade Chaves, J. F. (2026). Actualización en el Manejo de los Tumores Gástricos Neuroendocrinos: Una Revisión Narrativa. Ciencia Latina Revista Científica Multidisciplinar, 9(6), 10206-10233. https://doi.org/10.37811/cl_rcm.v9i6.22153
Número
Sección
Ciencias de la Salud
Derechos de autor 2026 Breidys Judith Arzuza Torres, Jose Manuel Bautista Bedoya, Ricardo Alfonso Cabrera Salgado, Lisbeth Lectamo Caicedo , Karen Natalia Estupiñan Alegría, Jesica Fernanda Andrade Chaves
Esta obra está bajo licencia internacional Creative Commons Reconocimiento 4.0.
.png)
.png)
1.png)
